Skip to content
lifestyle.ideacrossing.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Akagera Medicines Inc
Akagera Medicines Receives $7.8 Million Grant Expansion to Advance Dendritic Cell-Targeted mRNA Tuberculosis Vaccine Toward First-in-Human Trial
November 18, 2026
Akagera Medicines Reports Positive First-in-Human Data for Single-Ascending-Dose of AKG-100, Advancing a Potentially Transformative Long-Acting Therapeutic for Drug-Resistant Tuberculosis
July 20, 2026